Ionis Pharmaceuticals, Inc., a leading biotechnology company headquartered in the United States, is renowned for its pioneering work in RNA-targeted therapeutics. Founded in 1989, Ionis has established itself as a key player in the pharmaceutical industry, focusing on the development of innovative treatments for a range of serious diseases, including neurological disorders and cardiovascular conditions. With a robust pipeline of drugs, Ionis is particularly noted for its unique antisense technology, which allows for precise modulation of gene expression. This innovative approach has led to significant milestones, including the approval of several groundbreaking therapies. Ionis Pharmaceuticals continues to strengthen its market position through strategic partnerships and a commitment to advancing the field of genetic medicine, making it a notable force in the biopharmaceutical landscape.
How does Ionis Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Ionis Pharmaceuticals's score of 35 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Ionis Pharmaceuticals reported total Scope 1 and 2 greenhouse gas (GHG) emissions of approximately 5,146,000 kg CO2e, reflecting a 6% reduction from the previous year's emissions of about 5,483,000 kg CO2e. The company's Scope 2 emissions, primarily from purchased electricity, accounted for about 2,530,000 kg CO2e in 2024, down from approximately 2,788,000 kg CO2e in 2023. Ionis has set a near-term target to continue reducing its GHG emissions, achieving a 6% decrease in both Scope 1 and 2 emissions from 2023 to 2024. The company has not disclosed any Scope 3 emissions data, indicating a focus on direct and indirect emissions from its operations. The emissions intensity for Scope 1 and 2 was reported at about 4,870 kg CO2e per employee in 2024, down from approximately 6,110 kg CO2e per employee in 2023. This demonstrates Ionis's commitment to improving its operational efficiency and reducing its carbon footprint. Overall, Ionis Pharmaceuticals is actively working towards its climate commitments by implementing strategies to lower its GHG emissions, contributing to a more sustainable future.
Access structured emissions data, company-specific emission factors, and source documents
2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|
Scope 1 | 2,566,000,000 | - | - | - |
Scope 2 | 2,052,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Scope 3 | - | - | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ionis Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.